{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:04:17Z","timestamp":1793225057749,"version":"4.5.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the antimyeloma activity of IMiDs. CRBN depletion is initially cytotoxic to human myeloma cells, but surviving cells with stable CRBN depletion become highly resistant to both lenalidomide and pomalidomide, but not to the unrelated drugs bortezomib, dexamethasone, and melphalan. Acquired deletion of CRBN was found to be the primary genetic event differentiating isogenic MM1.S cell lines cultured to be sensitive or resistant to lenalidomide and pomalidomide. Gene expression changes induced by lenalidomide were dramatically suppressed in the presence of CRBN depletion, further demonstrating that CRBN is required for lenalidomide activity. Downstream targets of CRBN include interferon regulatory factor 4 (IRF4) previously reported to also be a target of lenalidomide. Patients exposed to, and putatively resistant to, lenalidomide had lower CRBN levels in paired samples before and after therapy. In summary, CRBN is an essential requirement for IMiD activity and a possible biomarker for the clinical assessment of antimyeloma efficacy.<\/jats:p>","DOI":"10.1182\/blood-2011-05-356063","type":"journal-article","created":{"date-parts":[[2011,8,23]],"date-time":"2011-08-23T01:50:37Z","timestamp":1314064237000},"page":"4771-4779","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":538,"title":["Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide"],"prefix":"10.1182","volume":"118","author":[{"given":"Yuan Xiao","family":"Zhu","sequence":"first","affiliation":[{"name":"Divisions of Hematology-Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[{"name":"Divisions of Hematology-Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Xin","family":"Shi","sequence":"additional","affiliation":[{"name":"Divisions of Hematology-Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Bruins","sequence":"additional","affiliation":[{"name":"Divisions of Hematology-Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica E.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Divisions of Hematology-Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Van Wier","sequence":"additional","affiliation":[{"name":"Divisions of Hematology-Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Bao","family":"Chang","sequence":"additional","affiliation":[{"name":"Biochemistry, Mayo Clinic, Scottsdale, AZ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad C.","family":"Bjorklund","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Divisions of Hematology-Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"Divisions of Hematology-Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"Divisions of Hematology-Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111807162314900_B1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents.","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019111807162314900_B2","first-page":"1750","article-title":"Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.","volume":"118","author":"Tiedemann","year":"2008","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111807162314900_B3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111807162314900_B4","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2008.402","article-title":"Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).","volume":"23","author":"Kastritis","year":"2009","journal-title":"Leukemia"},{"issue":"13","key":"2019111807162314900_B5","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma.","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2019111807162314900_B6","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111807162314900_B7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/CCO.0b013e32833d752c","article-title":"Recent advances of IMiDs in cancer therapy.","volume":"22","author":"Li","year":"2010","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"2019111807162314900_B8","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111807162314900_B9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"5971","key":"2019111807162314900_B10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity.","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"8","key":"2019111807162314900_B11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood-2009-09-243980","article-title":"Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.","volume":"115","author":"Tiedemann","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111807162314900_B12","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-08-3701","article-title":"Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.","volume":"69","author":"Braggio","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"2019111807162314900_B13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cmb.2006.13.215","article-title":"Efficient calculation of interval scores for DNA copy number data analysis.","volume":"13","author":"Lipson","year":"2006","journal-title":"J Comput Biol"},{"issue":"5853","key":"2019111807162314900_B14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1126\/science.1145720","article-title":"The genomic landscapes of human breast and colorectal cancers.","volume":"318","author":"Wood","year":"2007","journal-title":"Science"},{"issue":"13","key":"2019111807162314900_B15","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","article-title":"Evidence of a role for activation of Wnt\/\u03b2-catenin signaling in the resistance of plasma cells to lenalidomide.","volume":"286","author":"Bjorklund","year":"2011","journal-title":"J Biol Chem"},{"issue":"7201","key":"2019111807162314900_B16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma.","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"3","key":"2019111807162314900_B17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111807162314900_B18","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/blood-2010-10-314278","article-title":"IMiD immunomodulatory compounds block C\/EBP\u03b2 translation through eIF4E down-regulation resulting in inhibition of MM.","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2019111807162314900_B19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.292.292","article-title":"Secondary resistance to lenalidomide in Del(5q) MDS is associated with CDC25C and PP2A overexpression.","volume":"114","author":"List","year":"2009","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/18\/4771\/1463641\/zh804411004771.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/18\/4771\/1463641\/zh804411004771.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:17:58Z","timestamp":1574061478000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/18\/4771\/29339\/Cereblon-expression-is-required-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,3]]},"references-count":19,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2011,11,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-05-356063","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,3]]}}}